E3 Ubiquitin Ligases in Neurodevelopmental Disorders

Abstract

Highlights What are the main findings? • E3-related neurodevelopmental disorders are not limited to single E3 ubiquitin ligases but also involve E3 complex components, substrate recognition factors, and other regulatory proteins associated with ubiquitination; genetic abnormalities in different genes entail distinct genetic and functional consequences.• GO enrichment analysis and mechanistic evidence indicate that various E3-related abnormalities exhibit functional convergence in specific neurodevelopmental and cellular processes; however, the stages of therapeutic translation for these mechanisms differ significantly. What are the implications of the main findings? • UBE3A-related Angelman syndrome currently offers the clearest mechanism-based therapeutic pathway, whereas research into most non-UBE3A mechanisms remains at the stage of preclinical pathway analysis or candidate substrate validation.• Future studies need to further elucidate the specific functional consequences of various pathogenic variants, validate disease-relevant direct substrates and reproducible functional biomarkers, and consider factors such as developmental stage, dosage, and cell type in therapeutic development. Abstract Neurodevelopmental disorders (NDDs) comprise a heterogeneous group of conditions that may present with developmental delay, intellectual disability, language impairment, epilepsy, autism-like features, motor abnormalities, or syndromic manifestations. Ubiquitination is an essential post-translational mechanism that regulates protein stability, localization, trafficking, and signaling. Because E3 ubiquitin ligases determine substrate specificity in this process, abnormalities in E3 ligases or E3-associated complexes can selectively affect proteins required for brain development and neuronal function. This review summarizes genetic and functional evidence linking E3 ubiquitin ligases, E3-complex components, substrate-recognition factors, and related ubiquitination regulators to NDDs. Gene Ontology enrichment analysis and mechanistic studies suggest that these genes converge on several major biological themes, including early neurodevelopment, neuronal migration, synaptic and circuit maturation, proteostasis, metabolism, and intracellular trafficking. However, the strength and translational relevance of the available evidence vary across genes. UBE3A-related Angelman syndrome currently provides the clearest example of mechanism-guided therapeutic development through UBE3A restoration and paternal allele reactivation. In contrast, many non-UBE3A mechanisms remain at the stage of pathway analysis, preclinical modulation, or candidate substrate validation. Future studies should clarify variant-specific functional effects, define direct disease-relevant substrates, and establish reproducible readouts that can support mechanism-based therapeutic development.